+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

U

Actively Recruiting

Researchers are evaluating whether using an automated Carbon Dioxide CO2 injection system during infrainguinal peripheral vascular interventions PVI can reduce major adverse kidney events within 90 days in patients at moderately increased risk for contrast-associated acute kidney injury CA-AKI. This Phase 3 randomized controlled trial compares a CO2-based contrast medium sparing strategy to the standard use of iodinated contrast media in patients with peripheral vascular and kidney diseases. Participants are randomly assigned to one of two groups. The intervention group receives PVI using an automated CO2 injection system as the primary contrast agent, with iodinated contrast media available as a backup if image quality is insufficient or if the patient cannot tolerate CO2 angiography. The control group undergoes routine PVI using iodinated contrast media according to local standards, avoiding high-osmolar contrast agents. All patients are followed for up to 12 months after their procedure. During the study, participants undergo the planned PVI procedure with either contrast method. Researchers carefully record the amount and reasons for any iodinated contrast media used in the CO2 group. Patients are monitored for kidney-related outcomes, focusing on major adverse kidney events up to 90 days after the intervention. The trial includes ongoing follow-up assessments to evaluate safety and effectiveness over one year.

Age: 18Years +All GendersPhase 3
11 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations
O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
O

Actively Recruiting

Researchers are conducting a prospective, observational study to assess asthma control, health-related quality of life HRQL, lung function, and medication use in patients with severe eosinophilic asthma who are treated with benralizumab under routine care in Germany. The study aims to observe how these patients manage their asthma over time and how their treatment impacts their daily lives and health status. Participants receive benralizumab as part of their standard care, with no experimental treatment assigned by the study. The study lasts up to 52 weeks and monitors changes in asthma control using tools like the Asthma Control Test ACT and the Asthma Impairment and Risk Questionnaire AIRQ. Health-related quality of life is measured at baseline and follow-ups using the mini Asthma Quality of Life Questionnaire miniAQLQ. Patients also keep a weekly diary of their asthma medication intake, either on paper or electronically, to track any changes. Throughout the study, participants will have assessments at various time points up to one year after starting benralizumab. These include questionnaires on asthma control and quality of life, lung function tests, and biomarker measurements such as eosinophil levels and exhaled nitric oxide. Researchers analyze changes in medication doses and asthma symptoms, while patients regularly report their experiences. The study focuses on real-world outcomes without altering prescribed treatments, aiming to provide insights into the effects of benralizumab in everyday clinical practice.

Age: 18Years - 120YearsAll Genders
41 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.

Age: 18Years +All GendersPhase 3
317 locations
S

Actively Recruiting

Researchers are studying metastatic colorectal carcinoma mCRC patients who have a specific BRAFV600E mutation, which is linked to poorer outcomes compared to those without it. This mutation leads to shorter survival times after initial treatments, prompting the need for new therapy combinations. This research aims to observe how the drugs encorafenib and cetuximab work together in real-world settings for patients who have already received prior systemic therapies. This non-interventional, prospective, longitudinal study focuses on patients treated with encorafenib plus cetuximab following prior systemic therapy. The study collects data on treatment effectiveness, safety, and quality of life among a broader patient population in Germany, Austria, and Switzerland. Patients may have started treatment up to three months before joining the study or plan to start soon, and the study observes their outcomes without influencing treatment decisions. Participants will be monitored through data collection on their disease and treatment profiles, including patient and physician assessments, adverse events, and treatment details. The main outcome measured is overall survival at 12 months after starting treatment. Additional information gathered includes treatment duration, dose intensity, interruptions, and patient-reported quality of life using questionnaires. Safety and tolerability are also evaluated throughout treatment, with follow-up averaging nine months.

Age: 18Years +All Genders
70 locations
P

Actively Recruiting

Researchers are evaluating whether using a reminder app alongside standard skin care helps reduce the occurrence of moderate to severe radiation dermatitis in female breast cancer patients receiving adjuvant radiotherapy. This multinational, randomized trial compares standard skin care alone to standard skin care supported by an app that reminds patients to perform skin care four times daily. The study also looks at pain levels, patient satisfaction with the app, and how the app affects the use of health technology, especially in different age groups. Participants receive radiotherapy over about three to four weeks using hypo-fractionated doses, with some patients receiving additional radiation boosts based on age and risk factors. All patients perform standard skin care, which includes applying fatty cream with urea and possibly mometasone furoate cream in the app-supported group, patients also receive reminders and guidance through the app. The app allows patients to set notification schedules, postpone care reminders, and earn points for adherence. Patients in the app group will complete a questionnaire on their satisfaction and the apps impact at the end of treatment. During the study, radiation dermatitis is assessed weekly and at the end of radiotherapy by trained observers. Pain scores and patient satisfaction are also measured throughout the approximately four-week treatment period. Data on the apps use and support benefits are collected from the app group. The study includes 268 female patients aged 18 years and older with invasive breast cancer, who can use a smartphone and provide consent. Safety and compliance are monitored, with statistical analysis planned to compare outcomes between groups.

Age: 18Years +FEMALEPhase Not Applicable
5 locations
P

Actively Recruiting

This research aims to gather detailed data and biomaterials from adults diagnosed with Acute Lymphoblastic Leukemia ALL and related diseases, including certain types of Leukemia and Non-Hodgkins Lymphoma. The registry supports ALL research and quality assurance by collecting information regardless of whether patients participate in clinical trials. The study is observational and involves adults diagnosed and treated under ALL protocols. Participants include adults aged 18 and older with ALL subtypes, other leukemias treated according to ALL protocols, and specific subtypes of Non-Hodgkins Lymphoma treated under B-ALL protocols. The study collects data prospectively on diagnosis, treatment, and outcomes, along with biomaterials related to these conditions. Participants provide information during routine clinical care and follow-up visits for up to 10 years. Data collected includes survival rates, remission status assessed by various methods including PET scans, relapse rates, quality of life questionnaires, and monitoring of toxicities and comorbidities. The study tracks overall survival and other outcomes over long-term follow-up to support research and quality assurance in adult ALL and related diseases.

Age: 18Years +All Genders
147 locations
S

Actively Recruiting

Researchers are investigating treatments for adults diagnosed with acute myeloid leukemia AML or MDSAML that have a mutation in the IDH1 gene and who cannot undergo intensive chemotherapy. The study evaluates whether adding the drug venetoclax to the existing standard treatment of ivosidenib and azacitidine improves patient outcomes compared to a placebo. The safety and effectiveness of venetoclax are key focuses of this phase 3 trial. Participants receive either venetoclax or a placebo alongside ivosidenib and azacitidine. Treatments are given in continuous 28-day cycles and continue until disease relapse, progression, unacceptable side effects, death, withdrawal, or other protocol-defined reasons for stopping. The trial uses a triple-blind, randomized design to fairly compare the two treatment groups. During the study, researchers will monitor event-free survival as the primary outcome, assessing patients for signs of disease control or progression up to 12 months after the last patient is included. Secondary measures include overall survival, response rates, transfusion independence, and the duration and timing of responses. Participant involvement includes regular assessments, blood tests, and monitoring for side effects throughout the treatment period and follow-up.

Age: 18Years +All GendersPhase 3
119 locations
R

Actively Recruiting

Researchers are conducting a registry study involving adult patients diagnosed with acute myeloid leukemia AML and related myeloid neoplasms, including newly diagnosed or relapsedrefractory cases. The study aims to collect comprehensive data on patient characteristics, family history, biological disease profiles, and clinical outcomes. It also focuses on analyzing disease-related genetic markers and the impact of measurable residual disease MRD using various methods. The study does not involve specific treatments but collects data and biological samples such as bone marrow, blood, plasma, and normal tissue including skin biopsies and other specimens. This observational study enrolls patients from around 80 to 90 sites in Germany and Austria. Patients treatment responses, decisions, and outcomes are tracked over time. Participants are observed for up to 10 years, during which researchers gather information on treatment response, survival, relapse rates, quality of life, and genetic markers. The study includes assessments of event-free survival, relapse-free survival, cumulative incidence of relapse and death, and overall survival. Patient consent is required for registration, data storage, and biobanking of specimens for analysis throughout the observation period.

Age: 18Years +All Genders
94 locations

1-10 of 13

1